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Abstract
Improved understanding of the hepatitis C virus (HCV) life cycle has led to the discovery of numerous potential targets for antiviral
therapy. HCV polyprotein processing and replication have been identiﬁed as the most promising viral targets. However, viral entry and
fusion, RNA translation, virus assembly and release and several host cell factors may provide alternative attractive targets for future
anti-HCV therapies. Inhibitors of the HCV NS3/4A protease are currently the most advanced in clinical development. Monotherapy with
protease inhibitors has shown high antiviral activity, but is associated with frequent selection of resistant HCV variants, often resulting
in viral breakthrough. However, there is encouraging evidence from phase 2/3 trials indicating that the addition of a protease inhibitor
(e.g. telaprevir and boceprevir) to pegylated interferon-a/ribavirin substantially improves sustained virological response rates in both
treatment-naı¨ve and treatment-experienced patients with HCV genotype 1. Nucleos(t)ide inhibitors of the HCV NS5B polymerase have
shown variable antiviral activity against different HCV genotypes, but seem to have a higher genetic barrier to resistance than protease
inhibitors. In addition, several allosteric binding sites have been identiﬁed for non-nucleoside inhibitors of the NS5B polymerase. How-
ever, the development of a substance with high antiviral activity and a high genetic barrier to resistance seems to be difﬁcult. Among
the different host cell-targeting compounds in early clinical development, cyclophilin inhibitors have shown the most promising results.
Although advances have also been made in improving interferons, combinations of antiviral agents with different mechanisms of action
may lead to the eventual possibility of interferon-free regimens.
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Introduction
Chronic hepatitis C represents a major health burden, affect-
ing approximately 170 million people worldwide [1]. With
the current standard of care (SOC), a combination of pegy-
lated interferon (PEG-IFN)-a plus weight-based ribavirin
(RBV), viral eradication can be achieved in fewer than half of
all patients with hepatitis C virus (HCV) genotype 1 and in
approximately 80% of patients with HCV genotype 2 or 3
[2–5]. Treatment may take up to 72 weeks [6], but therapy-
associated side effects such as pancytopenia, ﬂu-like symp-
toms or depression are commonly observed, and may lead
to early treatment discontinuation.
Improved understanding of the HCV life cycle in recent
years has supported the development of direct-acting
antiviral (DAA) agents that speciﬁcally target post-transla-
tional processing and HCV replication [7–10]. Inhibitors of
HCV entry, HCV RNA translation and virus assembly and
release are mostly still in preclinical development, whereas
several host cell-targeting compounds rate among the
more promising therapeutic approaches in recent anti-HCV
drug discoveries. Finally, improvements have also been
made in the development of new, long-acting interferons
with the potential for more favourable safety and efﬁcacy
proﬁles.
This review will give an overview of recent developments
in the HCV drug pipeline. DAA agents, host cell-targeting
compounds and new interferons that have already been eval-
uated in clinical trials will be discussed. Other treatment
approaches, such as toll-like receptor agonists and therapeu-
tic vaccines, are beyond the scope of this article.
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Antivirals Targeting HCV Polyprotein
Processing
NS3/4A protease inhibitors
The NS3/4A protease has been recognized as an important
target for anti-HCV therapy because of its key role within
the HCV life cycle (e.g. cleavage of the genome-encoded
polyprotein and inactivation of cellular proteins required for
innate immunity). NS3/4A protease inhibitors have shown
strong antiviral efﬁcacy but a low genetic barrier to resis-
tance in early clinical studies. They can be divided into two
chemical classes: macrocyclic inhibitors, and linear, tetrapep-
tide a-ketoamide derivates (Fig. 1).
The clinical proof-of-concept for NS3/4A protease inhibi-
tors was obtained with ciluprevir, a macrocyclic NS3/4A pro-
tease inhibitor that showed substantial antiviral activity in
patients with HCV genotype 1 [11]. However, the develop-
ment of ciluprevir was stopped because of serious cardiotox-
icity in a monkey model.
Telaprevir
The orally bioavailable, linear, ketoamide protease inhibitor
telaprevir was initially investigated in a 14-day randomized,
placebo-controlled monotherapy study in patients with HCV
genotype 1 [12]. In this study, the greatest reduction in HCV
RNA was achieved in patients who received 750 mg of tela-
previr every 8 h, with a median viral load decline of
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FIG. 1. Antiviral activity of (a) NS3/4A protease inhibitors, (b) nucleos(t)ide analogue NS5B polymerase inhibitors, (c) non-nucleoside analogue
NS5B polymerase inhibitors and (d) NS5A and other inhibitors during monotherapy for 3–14 days in patients with chronic hepatitis C, modiﬁed
from [9]. No head-to-head studies were conducted. *Alinia was administered at a dose of of 500 mg twice daily for 24 weeks in genotype 4
patients only. BW, body weight; HCV, hepatitis C virus; IV, intravenous.
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4.4 log10 IU/mL HCV RNA from baseline. Viral rebound
caused by selected drug-resistant mutants occurred in the
majority of patients during treatment [13]. Mutations associ-
ated with clinical resistance to telaprevir were identiﬁed at
four positions of the NS3 catalytic domain — V36A/M/L,
T54A, R155K/M/S/T and A156S (all three conferring low-
level to medium-level resistance) and A156T/V (conferring
high-level resistance) [13–16].
In two short-term studies of telaprevir, given in combina-
tion with PEG-IFN-a-2a ± RBV for 2–4 weeks, an even more
pronounced viral decline, with a reduced frequency of resis-
tance mutations and no viral breakthrough, was observed
[17,18].
Subsequently, two large phase 2b placebo-controlled trials
of telaprevir in combination with PEG-IFN-a ± RBV were
conducted in treatment-naı¨ve patients with HCV genotype 1
in the USA (PROVE 1; n = 250) [19] and in Europe
(PROVE 2; n = 323) [20]. Overall, sustained virologic
response (SVR) rates of up to 67–69% were achieved in the
telaprevir-containing study arms vs. 41–46% in patients who
received SOC. In PROVE 1, only patients who achieved an
extended rapid virological response (eRVR) (HCV RNA neg-
ative at week 4 and thereafter) were eligible for a shortened
treatment duration. The exploratory study arms with
12 weeks of telaprevir plus PEG-IFN-a ± RBV were associ-
ated with high relapse rates, especially in patients without
RBV (up to 48%), indicating that 12 weeks of overall therapy
was insufﬁcient to achieve favourable treatment outcomes,
and highlighting the importance of adding RBV, because of
improved antiviral activity, reduced relapse rates, and a smal-
ler number of patients with selection of resistant variants
and viral breakthrough. Rates of treatment discontinuation
attributable to adverse events were higher in the telaprevir-
containing study arms than in patients treated with SOC
alone (12–21% vs. 7–11%). Moreover, discontinuation rates
increased to nearly 30% in patients who received telaprevir
for 24 weeks. Thus, in subsequent studies, telaprevir dosing
was restricted to a maximum of 12 weeks.
For more convenient application and to increase treat-
ment adherence, telaprevir every 12 h at a dose of 1125 mg
was investigated in a small open-label phase 2 study, con-
ducted in treatment-naı¨ve patients with HCV genotype 1
(study C208). In this study, telaprevir was also given in com-
bination with PEG-IFN-a-2b and RBV. Equally high SVR rates
were observed with telaprevir every 12 h vs. every 8 h, and
with PEG-IFN-a-2b vs. PEG-IFN-2a [21]. However, differ-
ences between the two PEG-IFN formulations may only
become visible in a more difﬁcult-to-treat patient population
(i.e. patients with high viral load, advanced ﬁbrosis or prior
non-response to PEG-IFN-a therapy). Telaprevir was also
investigated in patients infected with HCV genotypes 2, 3
and 4, with varying success [22,23].
The two pivotal phase 3 studies, known as ADVANCE
and ILLUMINATE, were conducted in more than 1500 treat-
ment-naı¨ve patients infected with HCV genotype 1, and
showed SVR rates of 75% and 72% following triple therapy
for 12 weeks followed by PEG-IFN-a-2a/RBV for an addi-
tional 12 or 36 weeks, respectively. Thus, SVR could be
increased by approximately 30% as compared with control
patients treated with SOC for 48 weeks (44%). Patients who
received triple combination therapy for 8 weeks, followed by
SOC for 16 or 40 weeks, still achieved an SVR rate of 69%
(ADVANCE). Precise plans for the management of adverse
events, especially the frequently observed rashes, were
developed for the phase 3 studies, and rates of discontinua-
tion attributable to adverse events were somewhat lower
than in the PROVE trials (7–8% vs. 4% in patients receiving
SOC) [24,25]. In the ADVANCE study, a response-guided
therapy approach was applied, with a shortened treatment
period of 24 weeks, in patients who achieved an eRVR,
whereas all other patients were treated for 48 weeks. In the
ILLUMINATE study, no beneﬁt of a longer treatment dura-
tion (48 weeks vs. 24 weeks) in eRVR patients could be
demonstrated (Fig. 2a).
Together, these ﬁndings show that an eRVR was achieved
in 57–65% of treatment-naı¨ve patients with HCV genotype 1.
Thus, the majority of patients were eligible for shortened
treatment duration, with equally high SVR rates as those
obtained with the standard therapy duration of 48 weeks.
Telaprevir in combination with PEG-IFN-a-2a ± RBV was
also investigated in treatment-experienced HCV genotype 1
patients (PROVE 3, n = 453; and study 107, n = 117) [26].
Overall, signiﬁcantly higher SVR rates were achieved in prior
relapsers who received triple combination therapy than in
those receiving SOC (up to 69–97% vs. 20%). Patients with
prior breakthrough or non-response achieved SVR rates in
the ranges of 57–86% and 38–39%, respectively, as compared
with 20% and 9% when given SOC. Prior non-responders,
including partial non-responders (‡2 log10 decline but detect-
able HCV RNA at treatment week 12) and null-responders
(<2 log10 decline in HCV RNA at week 12), experienced the
highest rates of viral breakthrough during triple combination
therapy.
A phase 3 study (REALIZE) of telaprevir evaluated the efﬁ-
cacy of a 12-week triple combination treatment regimen fol-
lowed by 36 weeks of SOC, or a 4-week lead-in with SOC,
followed by 12 weeks of triple combination therapy, fol-
lowed by 32 weeks of SOC in treatment-experienced geno-
type 1 patients (partial non-responders, null-responders and
relapsers) vs. SOC for 48 weeks. SVR rates for the three
124 Clinical Microbiology and Infection, Volume 17 Number 2, February 2011 CMI
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treatment arms were 64%, 66% and 17%, respectively. Prior
relapsers achieved SVR rates of 83–88%, whereas prior null-
responders achieved SVR rates in the range of 29–33%. Dis-
continuation because of adverse events occurred in 4% of
the combined telaprevir study arms and in 3% of the control
group. [27].
During triple therapy with telaprevir plus PEG-IFN-a/RBV,
viral breakthrough associated with the selection of resistant
variants was observed in 1–5% of treatment-naı¨ve patients
and in up to 25% of previous non-responders. Moreover,
variants conferring resistance to NS3 protease inhibitors
were also detected in patients with viral relapse after the
end of treatment. The long-term signiﬁcance of these resis-
tant variants is unknown but, generally, a decline in fre-
quency over time was observed. However, in single patients,
low to medium levels of the V36 and A156 variants were
observed for up to 4 years after telaprevir therapy [28].
Boceprevir
In a phase 1 study, administration of boceprevir (200
or 400 mg every 8 h), a peptidomimetic orally bioavailable
a-ketoamide HCV protease inhibitor, with or without PEG-
IFN-a-2b, resulted in mean maximum reductions of HCV
RNA of up to 1.61 log10 and 2.88 log10 IU/mL, respectively,
in treatment-experienced patients infected with HCV geno-
type 1 [29]. Subsequently, a number of mutations conferring
boceprevir resistance at low to medium levels were discov-
ered in vivo: V36M/A, T54A/S, V55A, R155K/T, A156S and
V170A [30–33]. As for telaprevir, reduced antiviral activities
of boceprevir in HCV genotype 2/3-infected patients were
reported.
In a phase 2 clinical trial (SPRINT-1), boceprevir (800 mg
every 8 h) in combination with PEG-IFN-a-2b and RBV was
investigated in treatment-naı¨ve patients with HCV geno-
type 1 (n = 595) [34]. Patients received either all three drugs
in combination for 28 or 48 weeks or for 24 or 44 weeks
after a previous 4-week lead-in phase of PEG-IFN-a-2b/RBV,
or SOC for 48 weeks. SVR rates ranged from 54% for
28 weeks of triple therapy to 75% after a 4-week lead-in
with PEG-IFN-a-2b/RBV followed by 44 weeks of triple ther-
apy, as compared with 38% in the control group. Treatment
discontinuations attributable to adverse events occurred in
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FIG. 2. Sustained viral response (SVR) results of recent telaprevir (ADVANCE, ILLUMINATE and REALIZE) and boceprevir (SPRINT-2 and
RESPOND-2) trials. No head-to-head studies were conducted. (a) ADVANCE and ILLUMINATE were conducted in treatment-naı¨ve patients
with hepatitis C virus (HCV) genotype 1. The ADVANCE treatment arms were as follows: (i) 12 weeks of telaprevir (T) plus PEG-IFN-a-2a and
ribavirin (PR) followed by PR for 12 or 36 weeks, based on treatment response at weeks 4 and 12; (ii) 8 weeks of T plus PR followed by PR for
16 or 40 weeks, based on treatment response at weeks 4 and 12; and (iii) PR alone for 48 weeks. In the ILLUMINATE trial, patients who
achieved an extended rapid virological response (eRVR) were randomized to receive 12 weeks of T plus PR followed by PR for (i) 12 weeks or
(ii) 24 weeks. Treatment-experienced patients with HCV genotype 1 (REALIZE) received: (i) 12 weeks of T plus PR followed by PR for
36 weeks; (ii) a 4-week PR lead-in followed by T plus PR for 12 weeks, followed by PR alone for 32 weeks; or (iii) PR alone for 48 weeks. In
the REALIZE study, relapsers and non-responder (null-responder and partial non-responder) patients were enrolled. (b) The SPRINT-2 treat-
ment arms in treatment-naı¨ve patients with HCV genotype 1 were as follows: (i) 4-week lead-in with PEG-IFN-a-2b plus ribavirin (PR) followed
by 44 weeks of PR plus boceprevir (B); (ii) 4-week lead-in with PR followed by PR plus B for 24 weeks or followed by PR plus B for 24 weeks
and PR for an additional 20 weeks, based on treatment response at weeks 8 and 12; and (iii) PR alone for 48 weeks. A similar treatment sche-
dule was used in treatment-experienced genotype 1 patients (RESPOND-2): (i) 4-week lead-in with PR followed by PR plus B for 44 weeks; (ii)
4-week lead in with PR followed by PR plus B for 32 weeks or followed by PR plus B for 32 weeks and PR for an additional 12 weeks, based on
treatment response at weeks 8 and 12; and (iii) PR alone for 48 weeks.
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9–19% of patients receiving boceprevir as compared with 8%
in the control group.
In patients with prior non-response to SOC therapy, the
addition of boceprevir to PEG-IFN-a and RBV gave only
slightly increased SVR rates as compared with standard ther-
apy in a phase 2b study with suboptimal boceprevir/RBV dos-
ing (14% vs. 2%) [35].
The 4-week lead-in phase with PEG-IFN-a/RBV was intro-
duced into boceprevir phase 2 trials to decrease the proba-
bility of resistance development. During the lead-in, a viral
decline of >2 log10 IU/mL was induced in the majority of
treatment-naive patients, resulting in undetectable HCV
RNA levels in 60–64% of patients after an additional 4 weeks
of triple therapy (week 8 of overall treatment), whereas only
37–39% of patients without lead-in therapy achieved unde-
tectable HCV RNA levels after 4 weeks of triple therapy.
Numerically, lower breakthrough rates and higher SVR rates
were observed in patients with a lead-in period than in those
without induction therapy. The lead-in period may help in
the selection of the optimal triple-therapy duration for both
treatment-naı¨ve and treatment-experienced patients. How-
ever, in virological non-sustained responders treated with
telaprevir-based triple therapy, no beneﬁt of a lead-in-phase
was observed [27].
In subsequent phase 3 studies, a larger number of treat-
ment-naı¨ve (SPRINT-2; n = 1097) and treatment-experienced
(RESPOND-2; n = 403; partial non-responders and relapsers
only) patients with HCV genotype 1 infection were enrolled
to receive a 4-week lead-in treatment with PEG-IFN-a-2b/
RBV alone, followed by either 44 weeks of triple combina-
tion therapy or a response-guided schedule with the possibil-
ity of stopping therapy at week 28 or week 36 of overall
treatment duration, respectively. SVR rates were 63–66% in
treatment-naı¨ve patients and 59–66% in treatment-experi-
enced patients, as compared with 38% and 21% in the
respective control groups (Fig. 2b). Treatment discontinua-
tions attributable to adverse events occurred in 12–16% of
treatment-naı¨ve patients and in 8–12% of treatment-experi-
enced patients, as compared with 16% and 3% in the respec-
tive control groups [36,37].
Other protease inhibitors
A large number of NS3/4A protease active site inhibitors are
currently in early clinical development (Table 1a): danoprevir
(RG 7227/ITMN191), TMC435, vaniprevir (MK-7009),
BI 201335, narlaprevir (SCH900518), BMS-650032,
PHX 1766, ACH-1625, IDX320, ABT-450, MK-5172, GS-
9256 and GS-9451 have all been tested in phase 1 and/or
phase 2 clinical trials [38–52]. Overall, these compounds
exhibit high antiviral activity in HCV genotype 1 patients, and
recently reported phase 2 results showed SVR rates compa-
rable to those achieved with telaprevir and boceprevir [48–
50].
Potential advantages of the newer antiviral compounds
include improved pharmacokinetics (once-daily to twice-daily
dosing), broader genotypic activity and better tolerability. In
addition, ritonavir boosting is being investigated for a number
of protease inhibitors, including narlaprevir and danoprevir,
to reduce side effects and to enhance patient exposure to
the latter agents, thereby potentially overcoming resistance
and allowing less frequent dosing.
The resistance proﬁles of all NS3 protease inhibitors cur-
rently in clinical development overlap (Table 2) [9].
Antivirals Targeting HCV Replication
NS5B polymerase inhibitors
Two classes of NS5B polymerase inhibitors can be distin-
guished: nucleoside or nucleotide analogue inhibitors, which
mimic the natural substrates of the RNA-dependent RNA
polymerase and are incorporated into the elongated RNA,
where they act as chain terminators; and non-nucleoside ana-
logue inhibitors, representing a heterogeneous group of
compounds that bind to different allosteric enzyme sites,
resulting in a conformational protein change before the elon-
gation complex is formed.
Nucleos(t)ide inhibitors
Nucleos(t)ide inhibitors potentially show similar efﬁcacies
against all HCV genotypes, because the active centre of
NS5B is a highly conserved region. The ﬁrst nucleoside ana-
logue in development was valopicitabine (NM283, 2¢-C-meth-
ylcytidine/NM107). However, valopicitabine showed only
weak antiviral activity, and further drug development was
stopped because of gastrointestinal side effects [53]. The
nucleoside analogue R1626 (4¢-azidocytidine/PSI-6130)
showed marked antiviral activity when given at high doses
alone or in combination with PEG-IFN-a-2a/RBV. No viral
breakthrough was reported for either monotherapy or com-
bination therapy. However, further development was
stopped because of severe adverse events, including severe
lymphocytopenia with lethal outcomes [54,55].
Among the nucleos(t)ide analogues still in development,
RG 7128 is the most advanced. Week 12 interim results of a
phase 2 trial of RG 7128 in combination with PEG-IFN-a-2a/
RBV in treatment-naı¨ve genotype 1 or 4 patients have shown
early virological response rates of >80% and no resistance-
related viral breakthrough [56]. SVR rates have to be
awaited. Other nucleotide analogue inhibitors that are
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TABLE 1. New hepatitis C virus therapies in the pipeline
(a)
Drug name Company Target/active drug Study phase
NS3/4A protease inhibitors
Ciluprevir (BILN 2061) Boehringer Ingelheim Active site/macrocyclic Stopped
Boceprevir (SCH503034) Merck Active site/linear Phase 3
Telaprevir (VX-950) Vertex Active site/linear Phase 3
Danoprevir (RG 7227) InterMune/Roche Active site/macrocyclic Phase 2
TMC435 Tibotec/Medivir Active site/macrocyclic Phase 2
Vaniprevir (MK-7009) Merck Active site/macrocyclic Phase 2
BI 201335 Boehringer Ingelheim Active site/linear Phase 2
BMS-650032 Bristol-Myers Squibb Active site Phase 2
GS-9256 Gilead Active site Phase 2
ABT-450 Abbott/Enanta Active site Phase 2
Narlaprevir (SCH900518) Merck Active site/linear On hold
PHX 1766 Phenomix Active site Phase 1
ACH-1625 Achillion Active site Phase 1
IDX320 Idenix Active site/macrocyclic On hold
MK-5172 Merck Active site/macrocyclic Phase 1
VX-985 Vertex Active site Phase 1
GS-9451 Gilead Active site Phase 1
Nucleos(t)ide NS5B polymerase inhibitors
Valopicitabine (NM283) Idenix/Novartis Active site/NM107 Stopped
RG 7128 Roche/Pharmasset Active site/PSI-6130 Phase 2
IDX184 Idenix Active site On hold
R1626 Roche Active site/R1479 Stopped
PSI-7977 Pharmasset Active site Phase 2
Non-nucleoside NS5B polymerase inhibitors
BILB 1941 Boehringer Ingelheim NNI site 1/thumb 1 Stopped
BI 207127 Boehringer Ingelheim NNI site 1/thumb 1 Phase 2
MK-3281 Merck NNI site 1/thumb 1 Stopped
Filibuvir (PF-00868554) Pﬁzer NNI site 2/thumb 2 Phase 2
VX-916 Vertex NNI site 2/thumb 2 On hold
VX-222 Vertex NNI site 2/thumb 2 Phase 2
VX-759 Vertex NNI site 2/thumb 2 Phase 1
ANA598 Anadys NNI site 3/palm 1 Phase 2
ABT-333 Abbott NNI site 3/palm 1 Phase 2
ABT-072 Abbott NNI site 3/palm 1 Phase 2
Nesbuvir (HCV-796) ViroPharma/Wyeth NNI site 4/palm 2 Stopped
Tegobuvir (GS-9190) Gilead NNI site 4/palm 2 Phase 2
IDX375 Idenix NNI site 4/palm 2 Phase 1
NS5A inhibitors
BMS-790052 Bristol-Myers Squibb NS5A domain 1 inhibitor Phase 2
BMS-824393 Bristol-Myers Squibb NS5A inhibitor Phase 1
PPI-461 Presidio NS5A inhibitor Phase 1
AZD7295 AstraZeneca NS5A inhibitor Phase 1
(b)
Indirect inhibitors/unknown mechanism of action
NIM811 Novartis Cyclophilin inhibitor Stopped
SCY-635 Scynexis Cyclophilin inhibitor Phase 1
Alisporivir (Debio 025) Debiopharm/Novartis Cyclophilin inhibitor Phase 2
Nitazoxanide Romark PKR induction? Phase 2
Celgosivir Migenix a-Glucosidase inhibitor Phase 2
New interferons
Locteron (BLX-883) Biolex Interferon receptor type 1 Phase 2
PEG-rIL-29 (pegylated interferon-k) ZymoGenetics/BMS Interferon receptor type 3 Phase 2
Joulferon (albinterferon-a-2b) HGS/Novartis Interferon receptor type 1 Stopped
Double-stranded-RNA-activated protein kinase. PKR.
TABLE 2. Mutations conferring resistance to hepatitis C virus NS3 protease inhibitors; modiﬁed from [9]
V36A/M T54S/A V55A Q80R/K R155K/T/Q A156S A156T/V D168A/V/T/H V170A/T
Telaprevir (linear) a a
Boceprevir (linear) a
aa
Narlaprevir (linear)
Ciluprevir (macrocyclic)
Danoprevir (macrocyclic)
Vaniprevir (macrocyclic)
TMC435 (macrocyclic)
BI-201335 (linear)
aMutations associated with resistance in vitro but not described in patients
CMI Vermehren and Sarrazin New HCV therapies 127
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 122–134
currently in clinical development include PSI-7977 (a chirally
pure isomer form of PSI-7851) and IDX184 [57,58].
Allosteric, non-nucleoside inhibitors
The structure of the NS5B polymerase resembles a character-
istic ‘right-hand motif’, consisting of ﬁnger, palm and thumb
domains. At least four different allosteric binding sites have
been identiﬁed for the inhibition of the NS5B polymerase by
non-nucleoside inhibitors: a benzimidazole (thumb 1)-binding
site, a thiophene (thumb 2)-binding site, a benzothiadiazine
(palm 1)-binding site, and a benzofuran (palm 2)-binding site
[59,60]. As non-nucleoside inhibitors bind more distantly to
the active site of NS5B, resistant mutations occur more fre-
quently than for nucleos(t)ide analogues.
Non-nucleoside site 1 inhibitors (thumb 1/benzimidazole
site)
BI 207127, BILB 1941 and MK-3281 are non-nucleoside
site 1 inhibitors that have been shown to exhibit low to
medium antiviral activity in phase 1 clinical trials [61–63].
Four weeks of BI 207127 (600 mg three times daily) in com-
bination with PEG-IFN-a-2a/RBV resulted in a median reduc-
tion of 5.6 log10 HCV RNA in treatment-naı¨ve genotype 1
patients, and no viral breakthrough was observed [64].
Results of further studies have to be awaited. The further
development of BILB 1941 and MK-3281 was halted because
of gastrointestinal adverse events.
Non-nucleoside site 2 inhibitors (thumb 2/thiophene site)
The non-nucleoside site 2 inhibitor ﬁlibuvir (PF-00868554)
has shown medium antiviral activity in phase 1 clinical trials.
Interim results from a phase 1 trial investigating different
doses of ﬁlibuvir in combination with PEG-IFN-a-2a/RBV
for 4 weeks followed by SOC for 44 weeks have shown
similar SVR (at 12 weeks of follow-up) results for the dif-
ferent ﬁlibuvir groups and for the SOC group, indicating
that longer dosing with ﬁlibuvir is needed [65]. Other site 2
inhibitors include VX-759, VX-916 and VX-222 [66–68].
However, only VX-222 has progressed to phase 2 develop-
ment.
Non-nucleoside site 3 inhibitors (palm 1/benzothiadiazine
site)
A phase 2 trial of ANA598 in combination with PEG-IFN-a-
2a/RBV in treatment-naı¨ve patients with HCV genotype 1 is
currently ongoing. It was recently reported that 75% of
patients who received 400 mg of ANA598 twice daily
achieved undetectable HCV RNA levels at treatment
week 12 (complete early virological response (cEVR)) [69].
However, SVR rates have to be awaited. Other site 3 palm 1
inhibitors include ABT-072 and ABT-333, both of which have
entered phase 2 clinical trials [70].
Non-nucleoside site 4 inhibitors (palm 2/benzofuran site)
Monotherapy with HCV-796 (nesbuvir) showed low antiviral
activity in HCV genotype 1-infected patients, and resulted in
selection of resistant variants and viral breakthrough in sev-
eral patients. Further drug development was suspended
because of abnormal liver enzyme elevations in a subsequent
phase 2 study [71]. GS-9190 (tegobuvir) displayed low antivi-
ral activity in a phase 1 clinical study, and drug-resistant vari-
ants were observed [72]. However, GS-9190 has entered
phase 2 clinical trials, both in combination with SOC and
with the protease inhibitor GS-9256 ± RBV. Finally, IDX375
also binds to the palm pocket, and is currently in phase 1
clinical trials [73].
NS5A inhibitors
Inhibitors of NS5A are potentially active against all HCV
genotypes. BMS-790052 binds to domain I of the NS5A pro-
tein, which is crucial for the regulation of HCV replication,
assembly and release. Following promising results from a
phase 1 study, BMS-790052 is currently under investigation
in a number of phase 2 clinical trials. Recently, interim data
were released from a phase 2 study investigating different
doses of BMS-790052 in combination with SOC. Rapid viro-
logical response rates were 83% and 92% in patients who
received 10 and 60 mg BMS-790052 once daily, respectively.
In addition, undetectable HCV RNA levels at week 12
(cEVR) were observed in 83% of patients [74].
Other NS5A inhibitors that are in early clinical develop-
ment include BMS-824393, AZD7295 and PPI-461 [75–77].
DAA Combination Therapies
Interferon-associated side effects may limit treatment success
in a large number of patients. Therefore, one of the primary
future goals of DAA therapy is to control viral replication or
even to achieve SVR in interferon-free regimens. In the
INFORM-1 study, combinations of different doses of a poly-
merase inhibitor (RG 7128) and the NS3/4A protease inhibi-
tor danoprevir (RG 7227/ITMN191) were tested in both
treatment-naı¨ve and treatment-experienced patients with
HCV genotype 1 for up to 2 weeks. Up to 63% of treat-
ment-naı¨ve patients achieved undetectable HCV RNA levels
after 2 weeks of combination therapy, and only one patient
experienced viral rebound without exhibiting resistance
mutations [78]. HCV RNA negativity rates were somewhat
lower in treatment-experienced patients (25%).
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A number of other drug combinations are currently being
investigated. Dual, triple and quadruple therapy with GS-
9256 and GS-9190 alone or in combination with RBV or
PEG-IFN-a/RBV for up to 28 days revealed the importance
of RBV for the enhancement of antiviral activity and reduc-
tion of viral breakthrough [79]. Interferon-sparing triple com-
bination therapy with BI 201335 and BI 207127 (400 or
600 mg three times daily) plus RBV resulted in undetectable
HCV RNA after 4 weeks in all patients treated with the
higher dose of BI 207127 [80]. Finally, in an ongoing trial of
HCV genotype 1 null-responders treated with BMS-790052
plus BMS-650032 alone or in combination with PEG-IFN-a/
RBV for 24 weeks, 14/21 patients achieved cEVR, whereas all
patients with viral breakthrough (n = 6) were genotype 1a
patients, indicating that not all DAAs may be equally effective
in both HCV genotype 1a and 1b patients [81].
Overcoming drug resistance will be the primary challenge
in DAA combination therapy, and drug combinations that
have a genetic barrier of four or more mutations may be
required [82]. Future trials need to address the tolerability
and safety of long-term DAA administration, and whether
SVR can be achieved without the addition of PEG-IFN-a/
RBV.
Emerging Mechanisms
Emerging potential drug candidates in future anti-HCV thera-
pies include inhibitors of HCV entry, internal ribosome entry
site inhibitors, inhibitors of HCV assembly and release, and
a-glucosidase inhibitors. However, potential compounds are
currently still in preclinical or very early clinical develop-
ment.
Host cells may provide additional targets for antiviral ther-
apies, and several host cell-targeting inhibitors have entered
clinical development, with promising results.
Cyclophilin inhibitors
Cyclophilins are ubiquitous proteins in human cells, and are
involved in protein folding. Moreover, cyclophilins participate
in HCV replication as functional regulators of the HCV
NS5B polymerase.
The cyclophilin inhibitor Debio 025 (alisporivir) showed
antiviral activity in patients infected with different HCV geno-
types (1–4) during monotherapy and in combination studies
with PEG-IFN-a. Maximum log10 changes in HCV RNA of up
to 4.75 were observed in HCV genotype 1 or 4 patients
who received 1000 mg of Debio 025 in combination with
PEG-IFN-a-2a/RBV for 4 weeks [83]. There is one case
report of a genotype 3a patient who achieved SVR following
4 weeks of Debio 025 1000 mg/day as monotherapy [84].
No viral breakthrough has been observed in clinical studies
so far. However, selection of HCV variants resistant to De-
bio 025 with mutations clustering in the NS5A gene was
observed in the HCV replicon system [85,86].
SCY-635 is another non-immunosuppressive analogue of
cyclosporin A that exhibits potent suppression of HCV. Dif-
ferent doses of SCY-635 were investigated in patients
infected with HCV genotype 1, and a mean maximum decline
of 2.3 log10 IU/mL in viral load was observed after 15 days of
900-mg SCY-635 monotherapy [87]. No viral rebound was
observed during SCY-635 therapy. However, minimal evi-
dence of resistance selection was observed within NS5B [88].
Silibinin
Silymarin, an extract of milk thistle (Silybum marianum) with
antioxidant activity, has been used as self-medication for liver
diseases for centuries [89]. Silibinin is one of the six major
ﬂavonolignans in silymarin. Although its mechanism of action
and treatment efﬁcacy are not yet fully understood, it was
recently reported that silibinin inhibited HCV RNA-depen-
dent RNA polymerase activity [90]. However, its antiviral
action includes blocking of virus entry and transmission, pos-
sibly by targeting the host cell [91].
Intravenous silibinin was investigated in non-responders to
prior IFN-based antiviral therapy, and led to a signiﬁcant
decline in HCV RNA of between 0.55 and 3.02 log10 IU/mL
after 7 days, and a further decrease after an additional 7 days
in combination with PEG-IFN-a-2a/RBV, in the range of
1.63–4.85 log10 IU/mL [92]. Studies in larger patient cohorts,
including resistance analyses, are underway.
Nitazoxanide
Nitazoxanide (alinia) is a thiazolide that has been shown in vi-
tro to have activity against both hepatitis B virus and HCV.
The antiviral method of action of nitazoxanide is still
unknown, but it is believed that it inhibits viral glycoproteins
at the post-translational level (i.e. PKR induction). A phase 2
study of 500 mg of nitazoxanide twice daily for 12 weeks,
followed by nitazoxanide, PEG-IFN-a-2a ± RBV for
36 weeks, yielded an SVR rate of 79% in treatment-naı¨ve
genotype 4 patients [93]. However, a similar regimen in
treatment-naı¨ve genotype 1 patients yielded a week 12 SVR
rate of only 44% [94]. Further studies are warranted.
New Interferons
Albinterferon-a-2b (Joulferon) is a recombinant protein con-
sisting of interferon-a-2b fused to human albumin that can
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be administered every 2 weeks, owing to a longer half-life
than that of the currently marketed pegylated interferons.
The efﬁcacy and safety of albinterferon-a-2b administered
every 2 weeks in combination with RBV for 48 weeks in
patients infected with HCV genotype 1, and for 24 weeks in
patients infected with HCV genotype 2/3, were recently
studied in two large phase 3 clinical trials (ACHIEVE 1 and
ACHIEVE 2/3) that were designed to demonstrate the non-
inferiority of these regimens as compared with SOC [95,96].
Both studies achieved the primary objective. In patients with
HCV genotype 1, intention-to-treat SVR rates of 51%, 48.2%
and 47.3% were achieved for PEG-IFN-a-2a, albinterferon-a-
2b (900 lg) and albinterferon-a-2b (1200 lg), respectively.
For genotype 2/3-infected patients, intention-to-treat SVR
rates were 84.8%, 79.8% and 80%, respectively. The safety
proﬁle was similar between the different treatment regimens,
indicating that albinterferon-a-2b was not better tolerated
than PEG-IFN-a-2a. Owing to concerns expressed by the
regulatory authorities regarding the beneﬁt/risk ratio, further
development of albinterferon was recently suspended.
Locteron is a controlled-release formulation of interferon-
a-2b that can be administered every 2 weeks. Week 12
interim results from a phase 2b study have shown a similar
reduction in HCV RNA and a reduction of ﬂu-like symptoms
by 57% for locteron at a dose of 480 lg as compared with
PEG-IFN-a-2b in treatment-naı¨ve patient with HCV geno-
type 1 [97]. SVR results have to be awaited.
PEG-IFN-k (PEG-rIL-29) is a type III interferon that binds
to a unique receptor with a more limited distribution than
the type I interferon receptor used by interferon-a. In a pha-
se 1b trial, 56 treatment-naı¨ve and SOC relapser patients
were enrolled to receive different doses of PEG-IFN-k (rang-
ing from 0.5 to 3.0 lg/kg) administered every 2 weeks or
weekly with or without daily RBV for 4 weeks. Antiviral
activity was seen at all dose levels, with a mean maximum
change of HCV RNA from baseline of 3.27 log10 IU/mL in
treatment-naı¨ve patients treated with weekly PEG-IFN-k
(1.5 lg/kg) plus RBV [98]. Phase 2 trials are currently
ongoing.
Conclusions
A number of advances have been made in the development
of new therapeutic options for the treatment of chronic hep-
atitis C. In particular, the challenges of treating patients with
HCV genotype 1 who achieve SVR rates in the range of 40–
50% with the current SOC have been met by the develop-
ment of DAA agents. Although monotherapy with DAAs
may not be suitable, owing to the selection of drug-resistant
HCV variants followed by viral breakthrough, convincing
results have been achieved for the combination of new anti-
viral agents with SOC.
Results from phase 2 clinical studies of the currently most
advanced compounds, telaprevir and boceprevir, have indi-
cated that the addition of an HCV protease inhibitor to
PEG-IFN-a/RBV signiﬁcantly improves SVR rates in both
treatment-naı¨ve and treatment-experienced patients. In addi-
tion, response-guided treatment schedules have been suc-
cessfully applied [19,20,26]. Thus, two of the major goals of
anti-HCV therapy, i.e. higher SVR rates and shorter treat-
ment duration based on RVR results, can be achieved.
The pivotal phase 3 trials of telaprevir and boceprevir in
treatment-naı¨ve patients infected with HCV genotype 1
recently conﬁrmed these promising results, showing SVR
rates ranging from 72% to 75% in telaprevir-treated patients
and from 63% to 66% in boceprevir-treated patients
[24,25,37].
Most HCV polymerase inhibitors have shown low to med-
ium antiviral activities during monotherapy studies. There-
fore, the future role of HCV polymerase inhibitors has yet
to be determined, and SVR data from larger studies with tri-
ple combination therapies have to be awaited. Unlike prote-
ase inhibitors, which are mostly active in patients with HCV
genotype 1 only, polymerase inhibitors bind to the highly
conserved centre of the HCV polymerase, with the possible
advantage of being equally effective for different HCV
genotypes.
With the addition of new antiviral compounds to standard
therapy, a number of additional side effects unrelated to
SOC have been observed, and increased treatment discon-
tinuation rates have been reported. In addition, frequent
dosing intervals (i.e. three times daily) may lead to increased
non-adherence outside of clinical trials, and more patient-
friendly formulations need to be developed.
One of the major challenges of future anti-HCV treatment
regimens will be the emerging ﬁeld of DAA drug resistance.
Relatively low genetic barriers to resistance have been
reported for HCV protease inhibitors and non-nucleoside
polymerase inhibitors as compared with nucleos(t)ide HCV
polymerase inhibitors, which appear to have a high genetic
barrier to resistance [9]. However, HCV eradication may
not be achieved by monotherapy with either substance
group, and drug combinations with non-cross-resistance pat-
terns have to be further evaluated. In addition, pre-existing
resistant variants and their potential long-term persistence
have to be taken into account for the selection of optimal
treatment and retreatment strategies. Although the addition
of PEG-IFN-a and RBV substantially reduces the frequency
of viral breakthrough caused by resistance development,
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combinations of different classes of DAA agents may eventu-
ally replace interferon-based regimens. Several trials address-
ing this issue are currently underway. In addition, the future
of hepatitis C therapy will probably involve individually tai-
lored treatment durations, based on viral kinetics, IL28B
polymorphisms and other parameters.
Besides compounds that target HCV polyprotein process-
ing or HCV replication, inhibitors of HCV entry and host
cell-targeting inhibitors (e.g. cyclophilin inhibitors) represent
further interesting strategies for future anti-HCV therapies.
Indeed, the cyclophilin inhibitor alisporivir (Debio 025) has
exhibited substantial antiviral efﬁcacy with and without SOC
in early clinical trials. As interferon and RBV are likely to
remain the backbone of anti-HCV therapy in the near future,
the development of new interferon formulations is also
underway, and preliminary study results have shown that
these may facilitate antiviral therapy without providing addi-
tional antiviral efﬁcacy.
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